The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 03, 2020

Filed:

Jul. 11, 2016
Applicant:

Teva Pharmaceuticals Australia Pty Ltd, Macquarie Park, NSW, AU;

Inventors:

Lynn Dorothy Poulton, Macquarie Park, AU;

Adam Clarke, Five Dock, AU;

Andrew James Pow, Pascoe Vale, AU;

Debra Tamvakis, Camberwell, AU;

George Kopsidas, Preston, AU;

Anthony Gerard Doyle, Drummoyne, AU;

Philip Anthony Jennings, Warrawee, AU;

Matthew Pollard, Dural, AU;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/24 (2006.01); C07K 16/28 (2006.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2875 (2013.01); C07K 16/241 (2013.01); G01N 33/6863 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/34 (2013.01); C07K 2317/55 (2013.01); C07K 2317/62 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01);
Abstract

The disclosure provides TNF-like ligand 1a (TL1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to TL1a and inhibits interaction of TL1a and Death Receptor 3 (DR3) and which does not inhibit the interaction of TL1a and Decoy Receptor 3 (DcR3). The disclosure also provides uses of the TL1a-binding proteins.


Find Patent Forward Citations

Loading…